ArticleBMJ open2020

Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China.

Li Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.